Cargando…

Differential effects of peritoneal and hemodialysis on circulating regulatory T cells one month post initiation of renal replacement therapy

Backgroundː Chronic kidney disease stage G5 (CKD G5) patients show an activated but impaired immune system. One function of the FOXP3(+) regulatory T (Treg) cells is to preserve tolerance to self while maintaining the ability to fight infectious agents. The aim of this pilot study is to evaluate lon...

Descripción completa

Detalles Bibliográficos
Autores principales: Caprara, Carlotta, Corradi, Valentina, Scalzotto, Elisa, Frigo, Anna C., Proglio, Marta, Sharma, Rahul, Ronco, Claudio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dustri-Verlag Dr. Karl Feistle 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9040198/
https://www.ncbi.nlm.nih.gov/pubmed/33074093
http://dx.doi.org/10.5414/CN110158
_version_ 1784694285495435264
author Caprara, Carlotta
Corradi, Valentina
Scalzotto, Elisa
Frigo, Anna C.
Proglio, Marta
Sharma, Rahul
Ronco, Claudio
author_facet Caprara, Carlotta
Corradi, Valentina
Scalzotto, Elisa
Frigo, Anna C.
Proglio, Marta
Sharma, Rahul
Ronco, Claudio
author_sort Caprara, Carlotta
collection PubMed
description Backgroundː Chronic kidney disease stage G5 (CKD G5) patients show an activated but impaired immune system. One function of the FOXP3(+) regulatory T (Treg) cells is to preserve tolerance to self while maintaining the ability to fight infectious agents. The aim of this pilot study is to evaluate longitudinal changes in Treg cells before and 1 month after the first dialysis treatment. Materials and methodsː CKD G5 patients not yet on dialysis were enrolled and started on hemodialysis (HD) or peritoneal dialysis (PD). Tregs were analyzed by flow cytometry at two time points: T0 (before the first dialysis treatment) and T1 (1 month after the first dialysis session). Wilcoxon test for dependent samples was used to compare the mean percentage difference between T0 and T1: Δ% = 100 × [(T1 – T0) / T0]. Resultsː 21 patients were enrolled: 8 on HD and 13 on PD. The proportion of total lymphocytes (low side scatter lymphocyte gate) and T lymphocytes (in the CD3(+)CD4(+) gate) did not change significantly 1 month after the start of dialysis in both groups. Treg cells (as CD25(+)FOXP3(+), FOXP3(+), or CD25(+)CD127(–)), analyzed as percentage of the lymphocyte gate, showed a significant increase post PD (CD25(+)FOXP3(+): median = 35.92; p = 0.0425; FOXP3(+): median = 30.85; p = 0.0479 and CD25(+)CD127(–): median = 23.71; p = 0.0215). The same populations, did not change 1 month after the first dialysis session. Conclusionː Our study is the first to evaluate longitudinal effects of dialysis on Treg cells in uremia and suggests that PD was more effective in increasing Treg levels 1 month post initiation of dialysis and may contribute to improvement of inflammatory status. Thus, PD may contribute to better outcomes for patients with renal dysfunction, also maintaining homeostasis of peritoneal and renal tissues.
format Online
Article
Text
id pubmed-9040198
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Dustri-Verlag Dr. Karl Feistle
record_format MEDLINE/PubMed
spelling pubmed-90401982022-04-26 Differential effects of peritoneal and hemodialysis on circulating regulatory T cells one month post initiation of renal replacement therapy Caprara, Carlotta Corradi, Valentina Scalzotto, Elisa Frigo, Anna C. Proglio, Marta Sharma, Rahul Ronco, Claudio Clin Nephrol Research Article Backgroundː Chronic kidney disease stage G5 (CKD G5) patients show an activated but impaired immune system. One function of the FOXP3(+) regulatory T (Treg) cells is to preserve tolerance to self while maintaining the ability to fight infectious agents. The aim of this pilot study is to evaluate longitudinal changes in Treg cells before and 1 month after the first dialysis treatment. Materials and methodsː CKD G5 patients not yet on dialysis were enrolled and started on hemodialysis (HD) or peritoneal dialysis (PD). Tregs were analyzed by flow cytometry at two time points: T0 (before the first dialysis treatment) and T1 (1 month after the first dialysis session). Wilcoxon test for dependent samples was used to compare the mean percentage difference between T0 and T1: Δ% = 100 × [(T1 – T0) / T0]. Resultsː 21 patients were enrolled: 8 on HD and 13 on PD. The proportion of total lymphocytes (low side scatter lymphocyte gate) and T lymphocytes (in the CD3(+)CD4(+) gate) did not change significantly 1 month after the start of dialysis in both groups. Treg cells (as CD25(+)FOXP3(+), FOXP3(+), or CD25(+)CD127(–)), analyzed as percentage of the lymphocyte gate, showed a significant increase post PD (CD25(+)FOXP3(+): median = 35.92; p = 0.0425; FOXP3(+): median = 30.85; p = 0.0479 and CD25(+)CD127(–): median = 23.71; p = 0.0215). The same populations, did not change 1 month after the first dialysis session. Conclusionː Our study is the first to evaluate longitudinal effects of dialysis on Treg cells in uremia and suggests that PD was more effective in increasing Treg levels 1 month post initiation of dialysis and may contribute to improvement of inflammatory status. Thus, PD may contribute to better outcomes for patients with renal dysfunction, also maintaining homeostasis of peritoneal and renal tissues. Dustri-Verlag Dr. Karl Feistle 2021-01 2020-10-19 /pmc/articles/PMC9040198/ /pubmed/33074093 http://dx.doi.org/10.5414/CN110158 Text en © Dustri-Verlag Dr. K. Feistle https://creativecommons.org/licenses/by/2.5/This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Caprara, Carlotta
Corradi, Valentina
Scalzotto, Elisa
Frigo, Anna C.
Proglio, Marta
Sharma, Rahul
Ronco, Claudio
Differential effects of peritoneal and hemodialysis on circulating regulatory T cells one month post initiation of renal replacement therapy
title Differential effects of peritoneal and hemodialysis on circulating regulatory T cells one month post initiation of renal replacement therapy
title_full Differential effects of peritoneal and hemodialysis on circulating regulatory T cells one month post initiation of renal replacement therapy
title_fullStr Differential effects of peritoneal and hemodialysis on circulating regulatory T cells one month post initiation of renal replacement therapy
title_full_unstemmed Differential effects of peritoneal and hemodialysis on circulating regulatory T cells one month post initiation of renal replacement therapy
title_short Differential effects of peritoneal and hemodialysis on circulating regulatory T cells one month post initiation of renal replacement therapy
title_sort differential effects of peritoneal and hemodialysis on circulating regulatory t cells one month post initiation of renal replacement therapy
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9040198/
https://www.ncbi.nlm.nih.gov/pubmed/33074093
http://dx.doi.org/10.5414/CN110158
work_keys_str_mv AT capraracarlotta differentialeffectsofperitonealandhemodialysisoncirculatingregulatorytcellsonemonthpostinitiationofrenalreplacementtherapy
AT corradivalentina differentialeffectsofperitonealandhemodialysisoncirculatingregulatorytcellsonemonthpostinitiationofrenalreplacementtherapy
AT scalzottoelisa differentialeffectsofperitonealandhemodialysisoncirculatingregulatorytcellsonemonthpostinitiationofrenalreplacementtherapy
AT frigoannac differentialeffectsofperitonealandhemodialysisoncirculatingregulatorytcellsonemonthpostinitiationofrenalreplacementtherapy
AT progliomarta differentialeffectsofperitonealandhemodialysisoncirculatingregulatorytcellsonemonthpostinitiationofrenalreplacementtherapy
AT sharmarahul differentialeffectsofperitonealandhemodialysisoncirculatingregulatorytcellsonemonthpostinitiationofrenalreplacementtherapy
AT roncoclaudio differentialeffectsofperitonealandhemodialysisoncirculatingregulatorytcellsonemonthpostinitiationofrenalreplacementtherapy